![](https://content.edgar-online.com/edgar_conv_img/2022/07/12/0001140361-22-025834_logo_femasys.jpg)
![](https://content.edgar-online.com/edgar_conv_img/2022/07/12/0001140361-22-025834_logo_femasys.jpg)
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Femasys Inc | NASDAQ:FEMY | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.88% | 1.14 | 1.13 | 9.50 | 1.29 | 1.00 | 1.13 | 681,439 | 05:00:00 |
• | being permitted to present only two years of audited financial statements and only two years of related Management’s Discussion and Analysis of Financial Condition and Results of Operations in this prospectus; |
• | not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended; |
• | reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and |
• | exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. |
• | 1,055,997 shares of common stock issuable upon the exercise of stock options outstanding as of March 31, 2022, with a weighted-average exercise price of $4.25 per share; |
• | 244,572 shares of common stock issuable upon the exercise of warrants to purchase shares of our common stock outstanding as of March 31, 2022, with a weighted-average exercise price of $12.64 per share; |
• | 1,319,136 shares of common stock reserved for future issuance under our 2021 Equity Incentive Plan, or 2021 Plan, as of March 31, 2022; and |
• | 284,707 shares of common stock reserved for future issuance under our 2021 Employee Stock Purchase Plan, or ESPP, as of March 31, 2022. |
• | our ability to develop and advance our current product candidates and programs into, and successfully initiate and complete, clinical trials; |
• | the ability of our clinical trials to demonstrate safety and effectiveness of our product candidates and other positive results; |
• | estimates regarding the total addressable market for our product candidates; |
• | our ability to enroll subjects in the clinical trials for our product candidates in order to advance the development thereof on a timely basis; |
• | our ability to obtain additional financing to fund the clinical development of our products and fund operations; |
• | competitive companies and technologies in our industry; |
• | our ability to obtain U.S Food and Drug Administration (FDA) approval for our permanent birth control system, ability to gain FDA grant of a de novo classification request for our intrauterine insemination system, expand sales of our women-specific medical products and develop and commercialize additional products; |
• | our ability to commercialize or obtain regulatory approvals, grants of de novo classification requests or 510(k) clearance for our product candidates, or the effect of delays in commercializing or obtaining regulatory authorizations; |
• | our business model and strategic plans for our products, technologies and business, including our implementation thereof; |
• | commercial success and market acceptance of our product candidates; |
• | our ability to achieve and maintain adequate levels of coverage or reimbursement for our FemBloc system or any future products we may seek to commercialize; |
• | our ability to manufacture our products and product candidates in compliance with applicable laws, regulations and requirements and to oversee third-party suppliers, service providers and vendors in the performance of any contracted activities in accordance with applicable laws, regulations and requirements; |
• | the impact of the COVID-19 pandemic on our business, financial condition, results of operations, and prospects; |
• | our ability to accurately forecast customer demand for our product candidates, and manage our inventory; |
• | our ability to build, manage and maintain our direct sales and marketing organization, and to market and sell our permanent birth control system, artificial insemination system and women-specific medical products in markets in and outside of the United States (U.S.); |
• | our ability to obtain necessary financing for the Company and maintain adequate resources to fund our operations; |
• | our ability to hire and retain our senior management and other highly qualified personnel; |
• | FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the U.S. and international markets; |
• | the timing or likelihood of regulatory filings and approvals or clearances; |
• | our ability to establish and maintain intellectual property protection for our product candidates and our ability to avoid claims of infringement; |
• | the volatility of the trading price of our common stock; and |
• | our expectations about market trends. |
Assumed public offering price per share | | | | | $2.41 | |
Net tangible book value per share as of March 31, 2022 | | | $1.99 | | | |
Increase in net tangible book value per share attributable to the offering | | | 0.07 | | | |
As adjusted net tangible book value per share after giving effect to the offering | | | | | 2.06 | |
Dilution per share to new investors participating in the offering | | | | | $0.35 |
• | 1,055,997 shares of common stock issuable upon the exercise of stock options outstanding as of March 31, 2022, with a weighted-average exercise price of $4.25 per share; |
• | 244,572 shares of common stock issuable upon the exercise of warrants to purchase shares of our common stock outstanding as of March 31, 2022, with a weighted-average exercise price of $12.64 per share; |
• | 1,319,136 shares of common stock reserved for future issuance under the 2021 Plan as of March 31, 2022; and |
• | 284,707 shares of common stock reserved for future issuance under the ESPP as of March 31, 2022. |
• | our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 24, 2022; |
• | our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, filed with the SEC on May 11, 2022; |
• | our Current Reports on Form 8-K filed with the SEC on January 20, 2022, February 24, 2022, and June 9, 2022, to the extent the information in such reports is filed and not furnished; and |
• | the description of our common stock contained in our Registration Statement on Form 8-A, filed with the SEC on June 14, 2021, including any amendments or reports filed for the purposes of updating this description. |
1 Year Femasys Chart |
1 Month Femasys Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions